Bioprinting company CELLINK has been granted a patent from the European Patent Office for a new technology for controlling the temperature of a printbed. The patent protects the technology in the European market.
The invention leverages the Peltier effect, resulting in a compact standalone system that is smaller and more robust than systems that use conventional thermoregulation methods.
Now, for research involving temperature-sensitive bioinks like collagen and GelMA, CELLINK’s temperature-controlled printbed promises reliable and precise control during the bioprinting process -- which is good news for users bioprinting retinal cells, heart cells, liver cells, cancer models and disease models. The patent complements a full portfolio of bioprinting solutions being developed at CELLINK.
Bioprinting different biomaterials relies on the ability to control each bioink’s individual rate of crosslinking. Conventional printbeds that use circuit boards, PCBs and film heaters pose problems in terms of accuracy and responsiveness, and typically lack a cooling function, according to the patent.
CELLINK set out to develop a different approach. The new printbed enables users to both raise and reduce temperature and the Peltier effect cools down the bioprinter much faster than older methods, offering more control to the user.
The method outlined in the patent makes a large step towards the ideal bioprinter and biomaterial-supporting technology.
The inventors include Erik Gatenholm and Héctor Martínez, co-founders of CELLINK, as well as Jockum Svanberg and Erik Sternå.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone: EU +46 73 267 00 00 Phone: +46 70 991 86 04
US +1 (650) 515 5566 US+1 (857) 332 2138
CELLINK is the leading 3D-bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at: email@example.com.